Page last updated: 2024-08-21

2-piperidone and Chronic Kidney Diseases

2-piperidone has been researched along with Chronic Kidney Diseases in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cho, JH; Choi, JY; Choi, SY; Kim, CD; Kim, YL; Oh, EJ; Park, SH; Ryu, HM	1
Cha, DR; Han, BG; Han, SY; Jang, Y; Jeong, KH; Jo, YI; Kang, SW; Kim, B; Kim, NH; Kim, SG; Na, KR; Oh, KH; Park, HC; Park, SH; Shin, S; Yoon, SA	1

Trials

1 trial(s) available for 2-piperidone and Chronic Kidney Diseases

Article	Year
Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40-week extension of the GUARD randomized study. Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:2 Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Monitoring; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Kidney; Linagliptin; Male; Middle Aged; Patient Dropouts; Piperidones; Pyrimidines; Renal Insufficiency, Chronic; Severity of Illness Index; Sulfonylurea Compounds	2018

Article

Year

Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40-week extension of the GUARD randomized study.

Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:2

Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Monitoring; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Kidney; Linagliptin; Male; Middle Aged; Patient Dropouts; Piperidones; Pyrimidines; Renal Insufficiency, Chronic; Severity of Illness Index; Sulfonylurea Compounds

2018

Other Studies

1 other study(ies) available for 2-piperidone and Chronic Kidney Diseases

Article	Year
Dipeptidyl peptidase-4 inhibitor gemigliptin protects against vascular calcification in an experimental chronic kidney disease and vascular smooth muscle cells. PloS one, 2017, Volume: 12, Issue:7 Topics: Adenine; Animals; Aorta, Abdominal; Calcium; Core Binding Factor Alpha 1 Subunit; Dipeptidyl-Peptidase IV Inhibitors; Frizzled Receptors; Gene Expression Regulation; Intercellular Signaling Peptides and Proteins; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; NADPH Oxidase 4; NADPH Oxidases; Phosphates; Phosphatidylinositol 3-Kinases; Piperidones; Primary Cell Culture; Proto-Oncogene Proteins c-akt; Pyrimidines; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Renal Insufficiency, Chronic; Transcription Factor Pit-1; Vascular Calcification; Wnt Signaling Pathway	2017

Article

Year

Dipeptidyl peptidase-4 inhibitor gemigliptin protects against vascular calcification in an experimental chronic kidney disease and vascular smooth muscle cells.

PloS one, 2017, Volume: 12, Issue:7

Topics: Adenine; Animals; Aorta, Abdominal; Calcium; Core Binding Factor Alpha 1 Subunit; Dipeptidyl-Peptidase IV Inhibitors; Frizzled Receptors; Gene Expression Regulation; Intercellular Signaling Peptides and Proteins; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; NADPH Oxidase 4; NADPH Oxidases; Phosphates; Phosphatidylinositol 3-Kinases; Piperidones; Primary Cell Culture; Proto-Oncogene Proteins c-akt; Pyrimidines; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Renal Insufficiency, Chronic; Transcription Factor Pit-1; Vascular Calcification; Wnt Signaling Pathway

2017